Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. “IBM has been at the forefront of creating generative AI models that extend AI’s impact beyond the domain of language,” said Alessandro Curioni, Vice President Accelerated Discovery, IBM Research. Together, Boehringer and IBM researchers will aim to accelerate the antibody discovery process through in-silico methods. These methods rely on new IBM foundation model technologies, designed to increase the speed and efficiency of antibody discovery and quality of predicted antibody candidates. Earlier this year, the company’s generative AI model efficiently predicted physico-chemical properties of drug-like small molecules.